title: Vitamin D Levels and Markers of Inflammation and Metabolism in HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
abstract: Data on vitamin D insufficiency as a cause of inflammation and metabolic dysfunction in HIV-infected individuals are conflicting. We examined the relationships between levels of 25-hydroxyvitamin D [25(OH)D] and biomarkers of inflammation and metabolism in stored blood samples from a prospective trial of vitamin D repletion. Blood samples from HIV-infected individuals on antiretroviral therapy (ART) with HIV-1 RNA <200 copies/ml enrolled in a prospective study were analyzed for 25(OH)D levels, a broad panel of cytokines, highly sensitive C-reactive protein, D-dimer, adiponectin, leptin, and insulin. Correlations between markers and 25(OH)D levels were determined. The Wilcoxon Rank Sum test was used to compare markers between individuals 25(OH)D insufficient and sufficient at baseline and before and after repletion among those who were insufficient and repleted to ≥30 ng/ml after 12 weeks. Of 106 subjects with stored plasma [66 with 25(OH)D <30 ng/ml and 40 ≥ 30 ng/ml], the median age was 50, the CD4 count was 515 cells/mm(3), 94% were male, and the median baseline 25(OH)D was 27 ng/ml. Higher 25(OH)D levels were associated with lower tumor necrosis factor (TNF)-α (r = -0.20, p = 0.04) and higher adiponectin levels (r = 0.30, p = 0.002). Following successful repletion to 25(OH)D ≥30 ng/ml there were no significant changes in inflammatory or metabolic parameters. Our study found associations between low 25(OH)D levels and TNF-α and adiponectin. Repletion did not result in changes in markers of inflammation or metabolism. These data support continued study of the relationship between vitamin D, inflammation, and metabolism in treated HIV infection.
authors.affiliation: 1 Department of Medicine, Division of Infectious Diseases, and Center for Clinical AIDS Research and Education (CARE), David Geffen School of Medicine, University of California , Los Angeles, Los Angeles, California.
authors.forename: Risa M
authors.initials: RM
authors.lastname: Hoffman
authors.affiliation: 1 Department of Medicine, Division of Infectious Diseases, and Center for Clinical AIDS Research and Education (CARE), David Geffen School of Medicine, University of California , Los Angeles, Los Angeles, California.
authors.forename: Jordan E
authors.initials: JE
authors.lastname: Lake
authors.affiliation: 2 Department of Medicine, Statistics Core, David Geffen School of Medicine, University of California Los Angeles , Los Angeles, California.
authors.forename: Holly M
authors.initials: HM
authors.lastname: Wilhalme
authors.affiliation: 2 Department of Medicine, Statistics Core, David Geffen School of Medicine, University of California Los Angeles , Los Angeles, California.
authors.forename: Chi-Hong
authors.initials: CH
authors.lastname: Tseng
authors.affiliation: 1 Department of Medicine, Division of Infectious Diseases, and Center for Clinical AIDS Research and Education (CARE), David Geffen School of Medicine, University of California , Los Angeles, Los Angeles, California.
authors.forename: Judith S
authors.initials: JS
authors.lastname: Currier
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood*; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D007249:Inflammation / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010949:Plasma / Q000737:chemistry; D011446:Prospective Studies; D014807:Vitamin D / Q000097:blood*
chemical_list: D044966:Anti-Retroviral Agents; D015415:Biomarkers; D014807:Vitamin D